Regulatory News:

MedinCell (Paris:MEDCL):

  • Philippe Guy is a former Global leader of the Boston Consulting Group's Healthcare Practice and member of BCG's Executive Committee.
  • He advised many global pharmaceutical and biotech companies on a large range of topics such as corporate and business unit level strategy, R&D process optimization and organization, commercial go-to-market strategies, as well as large-scale transformation and post-merger/acquisition integrations.
  • Philippe Guy has been actively participated to the growth of MedinCell as a board member, leading the Audit Committee during and post the IPO, and championing the integration of sustainable practices at the board level by creating and leading the ESG Committee.
  • As Chairman, he will leverage his vast experience to support the company management in crafting and implementing MedinCell's strategy

“After reaching the commercial stage with significant potential revenues on the horizon, MedinCell stands at a pivotal moment. Our opportunity is to anticipate and prepare for the future. Many levers exist to achieve sustainable and profitable growth: advancing our R&D pipeline, forging new partnerships, driving technology innovation. I am incredibly excited to share my expertise and contribute to supporting MedinCell's teams while preserving the mission and company model that have been key to our success”, states Philippe Guy.

With over 33 years of distinguished service at Boston Consulting Group (BCG), primarily within the healthcare sector, Philippe Guy has built a deep global expertise, working from Europe (London, Paris, Zurich), Japan, and North America. During his tenure, he played a pivotal role in developing BCG's Healthcare Practice Area across these regions. His leadership extended to steering the Global Healthcare Practice for nine years, further amplifying his impact on the industry. Additionally, he was peer-selected to represent all sector and functional practices on BCG's global Executive Committee, reflecting his broad strategic vision and leadership.

Philippe Guy is engaged on a pro-bono basis with the Foundation de la Mer, where his efforts are focused on scaling up its international impact. This includes contributing to key United Nations negotiations and facilitating the formation of coalitions among like-minded European foundations.

Besides MedinCell, Philippe also serves on the Board of Moleac, a Singapore-based company helping patients with brain injuries and neurological conditions.

Philippe Guy multifaceted career trajectory reflects a blend of strategic leadership in healthcare and a deep-seated commitment to ESG.

About MedinCell

MedinCell is a clinical- and commercial-stage biopharmaceutical company developing long-acting injectable drugs in many therapeutic areas. Our innovative treatments aim to guarantee compliance with medical prescriptions, to improve the effectiveness and accessibility of medicines, and to reduce their environmental footprint. They combine active pharmaceutical ingredients with our proprietary BEPO® technology which controls the delivery of a drug at a therapeutic level for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, entirely bioresorbable. The first treatment based on BEPO technology, intended for the treatment of schizophrenia, was approved by the FDA in April 2023, and is now distributed in the United States by Teva under the name UZEDY™ (BEPO technology is licensed to Teva under the name SteadyTeq™).

We collaborate with leading pharmaceutical companies and foundations to improve global health through new treatment options. Based in Montpellier, MedinCell currently employs more than 140 people representing more than 25 different nationalities.

UZEDY™ and SteadyTeq™ are trademarks of Teva Pharmaceuticals

This press release contains forward-looking statements, including statements regarding Company’s expectations for (i) the timing, progress and outcome of its clinical trials; (ii) the clinical benefits and competitive positioning of its product candidates; (iii) its ability to obtain regulatory approvals, commence commercial production and achieve market penetration and sales; (iv) its future product portfolio; (v) its future partnering arrangements; (vi) its future capital needs, capital expenditure plans and ability to obtain funding; and (vii) prospective financial matters regarding our business. Although the Company believes that its expectations are based on reasonable assumptions, any statements other than statements of historical facts that may be contained in this press release relating to future events are forward-looking statements and subject to change without notice, factors beyond the Company's control and the Company's financial capabilities.

These statements may include, but are not limited to, any statement beginning with, followed by or including words or phrases such as "objective", "believe", "anticipate", “expect”, "foresee", "aim", "intend", "may", "anticipate", "estimate", "plan", "project", "will", "may", "probably", “potential”, "should", "could" and other words and phrases of the same meaning or used in negative form. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that may, if any, cause actual results, performance, or achievements to differ materially from those anticipated or expressed explicitly or implicitly by such forward-looking statements. A list and description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the Autorité des Marchés Financiers (the "AMF") pursuant to its regulatory obligations, including the Company's registration document, registered with the AMF on September 4, 2018, under number I. 18-062 (the "Registration Document"), as well as in the documents and reports to be published subsequently by the Company. In particular, readers' attention is drawn to the section entitled "Facteurs de Risques" on page 26 of the Registration Document.

Any forward-looking statements made by or on behalf of the Company speak only as of the date they are made. Except as required by law, the Company does not undertake any obligation to publicly update these forward-looking statements or to update the reasons why actual results could differ materially from those anticipated by the forward-looking statements, including in the event that new information becomes available. The Company's update of one or more forward-looking statements does not imply that the Company will make any further updates to such forward-looking statements or other forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements.

This press release is for information purposes only. The information contained herein does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for the Company's shares in any jurisdiction, in particular in France. Similarly, this press release does not constitute investment advice and should not be treated as such. It is not related to the investment objectives, financial situation, or specific needs of any recipient. It should not deprive the recipients of the opportunity to exercise their own judgment. All opinions expressed in this document are subject to change without notice. The distribution of this press release may be subject to legal restrictions in certain jurisdictions. Persons who come to know about this press release are encouraged to inquire about, and required to comply with, these restrictions.

David Heuzé - Head of Communications / +33 (0)6 83 25 21 86

Head of US Financial Strategy & IR Grace Kim / +1 (646) 991-4023

Media Relations Nicolas Mérigeau / +33 (0)1 44 71 94 94

Investor Relations France Louis-Victor Delouvrier/Alban Dufumier / +33 (0)1 44 71 94 94

Medincell (EU:MEDCL)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024 Click aqui para mais gráficos Medincell.
Medincell (EU:MEDCL)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024 Click aqui para mais gráficos Medincell.